The estimated Net Worth of Mark R Bamforth is at least $3.33 million dollars as of 17 March 2021. Mr. Bamforth owns over 126,000 units of Avid Bioservices Inc stock worth over $3,157,560 and over the last 7 years he sold CDMOP stock worth over $0. In addition, he makes $167,482 as Independent Director at Avid Bioservices Inc.
Mark has made over 6 trades of the Avid Bioservices Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 126,000 units of CDMOP stock worth $2,290,680 on 17 March 2021.
The largest trade he's ever made was buying 126,000 units of Avid Bioservices Inc stock on 17 March 2021 worth over $2,290,680. On average, Mark trades about 27,077 units every 95 days since 2017. As of 17 March 2021 he still owns at least 126,000 units of Avid Bioservices Inc stock.
You can see the complete history of Mr. Bamforth stock trades at the bottom of the page.
Mark R. Bamforth serves as Independent Director of the Company. Mr. Bamforth is the Founder of Arranta Bio, LLC, a new contract development and manufacturing company (“CDMO”) that is being developed to support the microbiome industry. Previously, Mr. Bamforth served as the President and Chief Executive Officer of Brammer Bio, LLC, in Cambridge, Massachusetts, a cell and gene therapy CDMO with over 600 employees that he founded in 2015 and merged with Florida Biologix, an established, 10-year old CDMO, in March 2016. Brammer Bio was sold to Thermo Fisher Scientific on April 30, 2019. Previously, he was the President and Chief Executive Officer of Gallus Biopharmaceuticals, LLC (“Gallus”), in St. Louis, Missouri, a company that he founded in 2010. Gallus was a process development, clinical and commercial, mammalian cell based bulk biopharmaceuticals CDMO which tripled in size through organic growth and the acquisition of Laureate Biopharma, prior to its acquisition by DPx Holdings B.V., the parent company of Patheon, in 2014. Prior to this, Mr. Bamforth worked 22 years with Genzyme Corporation, in Cambridge Massachusetts, in roles of increasing responsibility, the last ten years of which were as senior vice president of corporate operations and pharmaceuticals. Mr. Bamforth earned a Bachelor of Science in chemical engineering from Strathclyde University and an MBA from Henley Management College. The Board of Directors concluded that Mr. Bamforth should serve as a director in light of his 30 plus years of biologics leadership experience and his extensive senior executive experience in overseeing the day-to-day business operations of, and successfully growing, both organically and through acquisitions, biologics contract manufacturing organizations.
As the Independent Director of Avid Bioservices Inc, the total compensation of Mark Bamforth at Avid Bioservices Inc is $167,482. There are 8 executives at Avid Bioservices Inc getting paid more, with Mark Ziebell having the highest compensation of $1,085,620.
Mark Bamforth is 57, he's been the Independent Director of Avid Bioservices Inc since 2017. There are 4 older and 5 younger executives at Avid Bioservices Inc. The oldest executive at Avid Bioservices Inc is Joseph Carleone, 74, who is the Independent Non-Executive Chairman of the Board.
Mark's mailing address filed with the SEC is 2642 MICHELLE DRIVE, SUITE 200, , TUSTIN, CA, 92780.
Over the last 7 years, insiders at Avid Bioservices Inc have traded over $326,500 worth of Avid Bioservices Inc stock and bought 164,445 units worth $426,401 . The most active insiders traders include Gregory Sargen, Mark R Bamforth et Richard B Hancock. On average, Avid Bioservices Inc executives and independent directors trade stock every 95 days with the average trade being worth of $895,669. The most recent stock trade was executed by Richard B Hancock on 10 September 2019, trading 10,000 units of CDMOP stock currently worth $50,900.
Avid Bioservices Inc executives and other stock owners filed with the SEC include: